CN101695494B - 硫酸头孢匹罗与柠檬酸钠的组合物 - Google Patents
硫酸头孢匹罗与柠檬酸钠的组合物 Download PDFInfo
- Publication number
- CN101695494B CN101695494B CN2009102335992A CN200910233599A CN101695494B CN 101695494 B CN101695494 B CN 101695494B CN 2009102335992 A CN2009102335992 A CN 2009102335992A CN 200910233599 A CN200910233599 A CN 200910233599A CN 101695494 B CN101695494 B CN 101695494B
- Authority
- CN
- China
- Prior art keywords
- sulfate
- sodium citrate
- cefpriome
- cefpirome sulfate
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 239000001509 sodium citrate Substances 0.000 title claims abstract description 40
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 title claims abstract description 40
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 title abstract 9
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 19
- 238000002347 injection Methods 0.000 claims abstract description 9
- 239000007924 injection Substances 0.000 claims abstract description 9
- RKTNPKZEPLCLSF-GNERTXCBSA-N OS([O-])(=O)=O.N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 Chemical compound OS([O-])(=O)=O.N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 RKTNPKZEPLCLSF-GNERTXCBSA-N 0.000 claims description 58
- 229960002838 cefpirome sulfate Drugs 0.000 claims description 56
- 239000003814 drug Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 12
- 239000012535 impurity Substances 0.000 abstract description 10
- 239000006184 cosolvent Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000007547 defect Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000005352 clarification Methods 0.000 description 28
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 230000007774 longterm Effects 0.000 description 8
- 229960000466 cefpirome Drugs 0.000 description 7
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229930186147 Cephalosporin Natural products 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011812 mixed powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- -1 (methoxy imino) acetyl Chemical group 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 238000010669 acid-base reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229960000484 ceftazidime Drugs 0.000 description 2
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 229960001790 sodium citrate Drugs 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 硫酸头孢匹罗(g) | 柠檬酸钠(g) | PH | 澄清度 |
1 | 1.0 | 0.30 | 2.94 | 澄清 |
2 | 1.0 | 0.48 | 3.89 | 澄清 |
3 | 1.0 | 0.6 | 4.18 | 澄清 |
4 | 1.0 | 0.7 | 4.41 | 澄清 |
5 | 1.0 | 0.8 | 4.61 | 澄清 |
6 | 1.0 | 0.9 | 4.72 | 澄清 |
7 | 1.0 | 1.0 | 4.86 | 澄清 |
8 | 1.0 | 2.0 | 5.43 | 澄清 |
组别 | 月份 | 硫酸头孢匹罗百分含量(%) | pH值 | 颜色 | 澄清度 | 相关杂质百分含量(%) |
1 | 0 | 87.1 | 2.94 | <Y3# | 澄清 | 0.6 |
1 | 86.9 | 2.97 | <Y3# | 澄清 | 0.6 | |
2 | 86.7 | 2.96 | =Y3# | 澄清 | 0.8 | |
3 | 86.6 | 2.95 | =Y3# | 澄清 | 1.0 | |
3 | 0 | 87.2 | 4.18 | <Y3# | 澄清 | 0.6 |
1 | 87.1 | 4.20 | <Y3# | 澄清 | 0.8 | |
2 | 86.7 | 4.14 | <Y3# | 澄清 | 0.9 | |
3 | 86.6 | 4.16 | <Y3# | 澄清 | 1.1 | |
4 | 0 | 87.0 | 4.41 | <Y3# | 澄清 | 0.7 |
1 | 86.9 | 4.45 | <Y3# | 澄清 | 0.9 | |
2 | 86.7 | 4.38 | <Y3# | 澄清 | 1.0 | |
3 | 86.7 | 4.40 | <Y3# | 澄清 | 1.1 | |
7 | 0 | 87.2 | 4.86 | <Y3# | 澄清 | 0.6 |
1 | 87.1 | 4.88 | <Y3# | 澄清 | 0.8 | |
2 | 86.9 | 4.86 | <Y3# | 澄清 | 1.0 | |
3 | 86.7 | 4.87 | =Y3# | 澄清 | 1.1 |
组别 | 月份 | 硫酸头孢匹罗百分含量(%) | pH值 | 颜色 | 澄清度 | 相关杂质百分含量(%) |
1 | 0 | 87.3 | 4.81 | <Y5# | 澄清 | 0.7 |
1 | 1 | 87.0 | 4.80 | <Y5# | 澄清 | 0.9 |
1 | 2 | 86.6 | 4.77 | =Y5# | 澄清 | 1.1 |
1 | 3 | 86.2 | 4.83 | <Y6# | 澄清 | 1.2 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102335992A CN101695494B (zh) | 2009-10-23 | 2009-10-23 | 硫酸头孢匹罗与柠檬酸钠的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102335992A CN101695494B (zh) | 2009-10-23 | 2009-10-23 | 硫酸头孢匹罗与柠檬酸钠的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101695494A CN101695494A (zh) | 2010-04-21 |
CN101695494B true CN101695494B (zh) | 2011-12-28 |
Family
ID=42140647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102335992A Expired - Fee Related CN101695494B (zh) | 2009-10-23 | 2009-10-23 | 硫酸头孢匹罗与柠檬酸钠的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101695494B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101475579A (zh) * | 2009-01-20 | 2009-07-08 | 广州白云山天心制药股份有限公司 | 一种稳定的头孢呋辛钠及其制备方法 |
-
2009
- 2009-10-23 CN CN2009102335992A patent/CN101695494B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101475579A (zh) * | 2009-01-20 | 2009-07-08 | 广州白云山天心制药股份有限公司 | 一种稳定的头孢呋辛钠及其制备方法 |
Non-Patent Citations (1)
Title |
---|
何玉每.注射用硫酸头孢匹罗的配药小技巧.《实用医药杂志》.2008,第25卷(第07期),840. * |
Also Published As
Publication number | Publication date |
---|---|
CN101695494A (zh) | 2010-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1879589A2 (en) | Treatment and control of severe infections including cystic fibrosis | |
CN102772360B (zh) | 一种兽用盐酸多西环素注射液及其制备方法 | |
CN102525963B (zh) | 一种硫酸奈替米星冻干粉针及其制备方法 | |
CN102860980A (zh) | 一种罗库溴铵注射液的制备方法 | |
CN101695494B (zh) | 硫酸头孢匹罗与柠檬酸钠的组合物 | |
CN103110640B (zh) | 一种注射用头孢唑肟钠和复方氨基酸注射液的药物组合物 | |
CN102210655B (zh) | 一种头孢匹胺钠微球及其制备方法 | |
CN101249092A (zh) | 一种抗感染的含有最佳配比的头孢哌酮钠和舒巴坦钠的药物组合物及其制备方法 | |
CN100356921C (zh) | 一种硫酸头孢匹罗组合物及其制备方法 | |
CN101574351A (zh) | 一种注射用头孢美唑制剂及其制备方法 | |
CN104189004A (zh) | 一种炉甘石洗剂的生产方法 | |
CN100508982C (zh) | 一种含有头孢曲松钠和盐酸利多卡因的注射用药物组合物 | |
CN103027894A (zh) | 注射用头孢他啶组合物及其制备方法 | |
EP2334298A2 (en) | Novel single unit carbapenem aminoglycoside formulations | |
CN101695493B (zh) | 头孢美唑酸与柠檬酸钠的组合物 | |
CN1857225A (zh) | 一种含有头孢曲松钠和盐酸利多卡因的注射用无菌分装制剂 | |
CN103230367B (zh) | 一种头孢泊肟酯组合物干混悬剂及其制备方法 | |
CN103655460B (zh) | 一种含氨曲南的注射用药物组合物及其制备方法和用途 | |
CN107789320A (zh) | 一种氟维司群缓释注射液及其制备工艺 | |
CN102600170A (zh) | 头孢替坦酸与柠檬酸钠的组合物 | |
CN117323301B (zh) | 一种高品质注射用头孢噻肟钠制剂及其制备方法 | |
CN1273139C (zh) | 一种左旋氧氟沙星软胶囊及其制备方法 | |
WO2019126910A1 (zh) | 含有哌拉西林的组合物、其药物制剂及其应用 | |
CN102885820A (zh) | 含有头孢噻呋双苄基乙二胺盐的药物组合物 | |
CN1813744A (zh) | 左旋加替沙星在静脉输注制剂的制备方法及由该方法制备的制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SINOPHARM GROUP ZHIJUN (SUZHOU) PHARMACEUTICAL CO. Free format text: FORMER NAME: SUZHOU ZHIJUN WANQING PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 215415 Taicang Regal Economic Development Zone, Jiangsu Patentee after: SINOPHARM ZHIJUN (SUZHOU) PHARMACEUTICAL CO.,LTD. Address before: 215415 Taicang Regal Economic Development Zone, Jiangsu Patentee before: SUZHOU ZHIJUN WANQING PHARMACEUTICAL Co.,Ltd. |
|
PP01 | Preservation of patent right |
Effective date of registration: 20200410 Granted publication date: 20111228 |
|
PP01 | Preservation of patent right | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20230410 Granted publication date: 20111228 |
|
PD01 | Discharge of preservation of patent | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111228 |
|
CF01 | Termination of patent right due to non-payment of annual fee |